Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects of Chinese descent with full Chinese parentage.~2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by endoscopy, radiologic evaluation, and/or histology during the Screening Period.~3. Crohn's Disease Activity Index (CDAI) ≥ 220 and ≤ 450 despite treatment with oral corticosteroids and/or immunosuppressants.~4. Subject has a negative Tuberculosis (TB) Screening Assessment.~Exclusion Criteria:~1. Subject with ulcerative colitis or indeterminate colitis.~2. Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.~3. Subject with an ostomy or ileoanal pouch.~4. Subject who has short bowel syndrome.~5. Subject with symptomatic known obstructive strictures.~6. Subject with an internal or external fistula (with the exception of an anal fistula without abscess).~7. Chronic recurring infections or active TB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Low Induction Dose (Type: EXPERIMENTAL): Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
- Standard Induction Dose (Type: EXPERIMENTAL): Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).